"Η υγεία απαιτεί ισχυρή βούληση", "Σωστά στοιχεία για σωστές αποφάσεις", "Διδάγματα από την οικονομική κρίση"
Εκδόσεις ΣΦΕΕ
-
-
Τρίπτυχο Vortal ΣΦΕΕ
-
ΣΦΕΕ Profile 2009
-
Τρίπτυχο Κώδικα Δεοντολογίας
-
Εγχειρίδιο Φαρμακοεπαγρύπνησης
-
Η Φαρμακευτική Αγορά στην Ελλάδα Γεγονότα & Στοιχεία
ΔΕΛΤΙΑ ΤΥΠΟΥ
-
Ανάπτυξη και Εφαρμογή του Ηλεκτρονικού Συστήματος Συνταγογράφησης18/02/2010
-
Θέσεις του ΣΦΕΕ για το νέο σύστημα τιμολόγησης17/02/2010
-
Δελτίο Τύπου ΣΦΕΕ21/01/2010
ΣΥΝΕΝΤΕΥΞΕΙΣ-ΑΡΘΡΑ
-
Χαιρετισμός του Δ. Φιλιώτη, Προέδρου ΣΦΕΕΕτήσια επετειακή εκδήλωση του Φαρμακευτικού Συλλόγου Λάρισας
Λάρισα, 23/1/2010
-
Συνέντευξη του Δ. Φιλιώτη, Προέδρου ΣΦΕΕΤίτλος: "Το ζήτημα δεν είναι η τιμή της ασπιρίνης"
Μηνιαία έκδοση με θέμα την Υγεία "IN VITRO", Δεκέμβριος 2009
ΕΙΔΗΣΕΙΣ
- 2009, ΟΚΤΩΒΡΙΟΣ 27 - 13:06 Transatlantic Administrative Simplification Action Plan – 2009 implementation reportDuring the recent annual EU-EMEA/FDA bilateral meeting the parties took stock of the progress achieved regarding the implementation of the Transatlantic Administrative Simplification Action Plan, agreed in June 2008.
- 2009, ΟΚΤΩΒΡΙΟΣ 12 - 09:42 Assessment of the functioning of the "Clinical Trials Directive” 2001/20/EC - Public consultation paperIn its Communication of 10 December 2008 to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on “Safe, Innovative and Accessible Medicines: a Renewed Vision for the Pharmaceutical Sector”1, the Commission announced that an assessment would be made of the application of Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use2 (“Clinical Trials Directive”). This assessment would consider, in particular, various options for further improving the functioning of the Clinical Trials Directive with a view to remedy shortcomings and unintended negative consequences while taking the global dimension of clinical trials into account.
- 2009, ΣΕΠΤΕΜΒΡΙΟΣ 29 - 16:25 Commission paves the way for vaccinations for influenza pandemic (H1N1) 2009Following the positive scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA) on 24 September, today the European Commission granted variations to two existing authorisations for vaccines for influenza pandemic (H1N1) 2009. The products concerned are Focetria® (Novartis), and Pandemrix® (GlaxoSmithKline). The vaccines will be authorised for use in all Member States of the EU and the EEA (Iceland, Liechtenstein and Norway). That should ensure that sufficient vaccines will be available before the start of the flu season and will reduce the risks for illnesses and deaths for European Citizens.
- 2009, ΣΕΠΤΕΜΒΡΙΟΣ 29 - 10:05 MRL - Substances considered as not falling within the scope of Council Regulation (EC) No. 470/2009 (Revision 17)Rivision 17 of the document Substances considered as not falling within the scope of Council Regulation (EC) No. 470/2009 (September 2009) is now available.















